[The clinical safety and efficacy of the patients of acute myeloid leukemia with FLT3-ITD positive treated with sorafenib in combination with venetoclax and azactitidine regimen].
作者信息
Ai H, Mi R H, Chen L, Ji X, Yin Q S, Wei X D, Song Y P
机构信息
Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2022 Nov 14;43(11):956-959. doi: 10.3760/cma.j.issn.0253-2727.2022.11.013.
Abstract
摘要
相似文献
1
[The clinical safety and efficacy of the patients of acute myeloid leukemia with FLT3-ITD positive treated with sorafenib in combination with venetoclax and azactitidine regimen].[索拉非尼联合维奈克拉及阿扎胞苷方案治疗FLT3-ITD阳性急性髓系白血病患者的临床安全性和疗效]
Zhonghua Xue Ye Xue Za Zhi. 2022 Nov 14;43(11):956-959. doi: 10.3760/cma.j.issn.0253-2727.2022.11.013.
2
Sorafenib in combination with intensive chemotherapy for relapsed or refractory FLT3-ITD positive acute myeloid leukemia: A two centers experience.索拉非尼联合强化化疗治疗复发或难治性FLT3-ITD阳性急性髓系白血病：两个中心的经验
Leuk Res. 2024 Jan;136:107421. doi: 10.1016/j.leukres.2023.107421. Epub 2023 Nov 18.
3
Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.索拉非尼和舒尼替尼序贯治疗 FLT3-ITD 阳性急性髓系白血病时出现多克隆 FLT3 酪氨酸激酶结构域突变。
Clin Cancer Res. 2013 Oct 15;19(20):5758-68. doi: 10.1158/1078-0432.CCR-13-1323. Epub 2013 Aug 22.
4
Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia.维奈克拉、FLT3抑制剂和地西他滨三联疗法治疗FLT3突变的急性髓系白血病。
Blood Cancer J. 2021 Feb 1;11(2):25. doi: 10.1038/s41408-021-00410-w.
5
Use of sorafenib for post-transplant relapse in FLT3/ITD-positive acute myelogenous leukemia: maturation induction and cytotoxic effect.索拉非尼在FLT3/ITD阳性急性髓性白血病移植后复发中的应用：成熟诱导和细胞毒性作用。
Haematologica. 2014 Nov;99(11):e222-4. doi: 10.3324/haematol.2014.109975. Epub 2014 Jul 11.
6
Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.FLT3 抑制剂治疗 FLT3 突变型急性髓系白血病与继发性 FLT3 酪氨酸激酶结构域突变的发生相关。
Cancer. 2014 Jul 15;120(14):2142-9. doi: 10.1002/cncr.28705. Epub 2014 Apr 15.
7
Sorafenib in Relapsed AML With FMS-Like Receptor Tyrosine Kinase-3 Internal Tandem Duplication Mutation.索拉非尼治疗 FMS 样酪氨酸激酶 3 内部串联重复突变复发性急性髓系白血病。
J Natl Compr Canc Netw. 2015 May;13(5):508-14. doi: 10.6004/jnccn.2015.0070.
8
Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia.阿扎胞苷作为索拉非尼诱导的Fms样酪氨酸激酶-3内部串联重复阳性急性髓系白血病缓解后的巩固治疗。
Haematologica. 2015 Jul;100(7):e250-3. doi: 10.3324/haematol.2014.123034. Epub 2015 Mar 27.
9
High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation.在异基因造血干细胞移植后复发的FLT3-ITD急性髓系白血病中，索拉非尼的血液学缓解率较高。
Eur J Haematol. 2016 Jun;96(6):629-36. doi: 10.1111/ejh.12647. Epub 2015 Sep 21.
10
Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.FLT3-ITD阳性急性髓系白血病的预后：异基因干细胞移植和酪氨酸激酶抑制剂治疗的影响
J Cancer Res Clin Oncol. 2017 Feb;143(2):337-345. doi: 10.1007/s00432-016-2290-5. Epub 2016 Oct 24.
本文引用的文献
1
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.阿扎胞苷和维奈托克治疗未经治急性髓系白血病。
N Engl J Med. 2020 Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971.
2
Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia.维奈托克与去甲基化药物治疗FLT3突变的急性髓系白血病
Am J Hematol. 2020 Oct;95(10):1193-1199. doi: 10.1002/ajh.25929. Epub 2020 Jul 28.
3
Venetoclax in acute myeloid leukemia - current and future directions.维奈托克治疗急性髓系白血病——现状与未来方向。
Leuk Lymphoma. 2020 Jun;61(6):1313-1322. doi: 10.1080/10428194.2020.1719098. Epub 2020 Feb 7.
4
Will new agents impact survival in AML?新的药物会影响 AML 的存活率吗？
Best Pract Res Clin Haematol. 2019 Dec;32(4):101094. doi: 10.1016/j.beha.2019.101094. Epub 2019 Oct 18.
5
Venetoclax-based therapies for acute myeloid leukemia.基于 Venetoclax 的急性髓系白血病疗法。
Best Pract Res Clin Haematol. 2019 Jun;32(2):145-153. doi: 10.1016/j.beha.2019.05.008. Epub 2019 May 24.
6
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.维奈托克联合地西他滨或阿扎胞苷治疗初治老年急性髓系白血病患者。
Blood. 2019 Jan 3;133(1):7-17. doi: 10.1182/blood-2018-08-868752. Epub 2018 Oct 25.
7
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.维奈托克单药治疗急性髓性白血病患者的II期研究中的疗效及反应的生物学关联
Cancer Discov. 2016 Oct;6(10):1106-1117. doi: 10.1158/2159-8290.CD-16-0313. Epub 2016 Aug 12.
8
IL-15 regulates Bcl-2 family members Bim and Mcl-1 through JAK/STAT and PI3K/AKT pathways in T cells.白细胞介素-15通过JAK/STAT和PI3K/AKT信号通路调控T细胞中Bcl-2家族成员Bim和Mcl-1。
Eur J Immunol. 2014 Aug;44(8):2500-7. doi: 10.1002/eji.201344238. Epub 2014 Jun 10.
9
Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.索拉非尼联合强化化疗治疗老年急性髓系白血病：一项随机、安慰剂对照试验的结果。
J Clin Oncol. 2013 Sep 1;31(25):3110-8. doi: 10.1200/JCO.2012.46.4990. Epub 2013 Jul 29.
10
Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.索拉非尼治疗耐药或复发急性白血病患者的 I 期研究。
Haematologica. 2011 Jan;96(1):62-8. doi: 10.3324/haematol.2010.030452. Epub 2010 Oct 15.
Zotero 插件